Horizons co-leads $15m funding round for Owlstone

Corporate venturing arm Aviva Ventures co-led the round, which also saw investment from existing investors.

The fresh capital will be used to bring the company's lung cancer test, Breath Biopsy, to market as well as deepen its pipeline of ongoing trials.

Previous funding
Owlstone raised $11.5m from unnamed investors in January 2017. Aviva Ventures injected a further £4m two months later.

Company
Owlstone span out of chemical detection company Owlstone in 2016. The company develops a breathalyser for the early detection of lung and colorectal cancer. Its Breath Biopsy platform is being deployed in the PAN cancer trial, a collaboration with Cancer Research UK. Owlstone is headquartered in Cambridge, UK.

People
Horizon Ventures – Patrick Zhang (investment professional).
Owlstone Medical – Billy Boyle (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture